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Felis catus papillomavirus type 2 (FcaPV-2) is a virus which commonly infects the skin of 
domestic cats. While most infections are asymptomatic, there is growing evidence that FcaPV-2 
may play a role in the development of a subset of feline cutaneous squamous cell carcinomas 
(SCCs).  
 
In the first part of this thesis, the natural history of FcaPV-2 infection was investigated with the 
aim of determining when cats become infected with the virus. A real-time PCR assay was 
developed to quantify FcaPV-2 DNA in feline skin swabs. This assay was then used to measure 
the FcaPV-2 DNA load in serial samples from two populations of cats. Results from these studies 
showed that most kittens are exposed to FcaPV-2 in the first few days of life. Additionally, the 
primary source of exposure is likely to be direct contact with other cats in the household, 
particularly their queen, as some of the queens appeared to be shedding large amounts of virus. 
FcaPV-2 mRNA was also detected in some of the kittens, confirming that they had become 
infected with FcaPV-2 soon after birth.  
 
The aim of the second part of this thesis was to determine the quantity and transcriptional 
activity of the FcaPV-2 DNA present in feline cutaneous SCCs in order to determine if the virus 
was involved in cancer development or just present as an innocent bystander. Real-time PCR 
assays were developed to measure FcaPV-2 gene expression in SCCs and the results clearly 
distinguished two subsets of feline cutaneous SCCs. The majority of the SCCs had low copy 
numbers of FcaPV-2 DNA and no FcaPV-2 gene expression, suggesting the virus was an incidental 
finding. In contrast, around a third of the SCCs had detectable FcaPV-2 gene expression and high 
copy numbers of FcaPV-2 DNA, similar to that found in the FcaPV-2-induced premalignant 
lesions. There was also a significant association between FcaPV-2 gene expression and 
alterations in a host cell cycle regulatory protein (p16). Taken together, these results strongly 
suggest that FcaPV-2 played a role in the development of around a third of the feline cutaneous 
SCCs.  
 
The results from the studies reported in this thesis support a causative role of FcaPV-2 in a 
proportion of feline cutaneous SCCs. However, as infection of cats is common and appears to 
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Domestic cats Phylogeny- genus Tissue infected 
FcaPV-1 Felis catus papillomavirus type 1 
Formerly Felis domesticus papillomavirus 1 
Lambdapapillomavirus oral mucosa 
FcaPV-2  Felis catus papillomavirus type 2 
Formerly Felis domesticus papillomavirus 2 
Dyothetapapillomavirus skin 
FcaPV-3 Felis catus papillomavirus type 3 Taupapillomavirus skin 
FcaPV-4 Felis catus papillomavirus type 4 Taupapillomavirus unknown 
Humans 
  
HPV-1 Human papillomavirus type 1 Chipapillomavirus skin 
HPV-2 Human papillomavirus type 2 Alphapapillomavirus skin 
HPV-4 Human papillomavirus type 4 Gammapapillomavirus skin 
HPV-5 Human papillomavirus type 5 Betapapillomavirus skin 
HPV-6 Human papillomavirus type 6 Alphapapillomavirus genital mucosa 
HPV-8 Human papillomavirus type 8 Betapapillomavirus skin 
HPV-9 Human papillomavirus type 9 Betapapillomavirus skin 
HPV-11 Human papillomavirus type 11 Alphapapillomavirus genital mucosa 
HPV-16 Human papillomavirus type 16* Alphapapillomavirus genital mucosa 
HPV-17 Human papillomavirus type 17 Betapapillomavirus skin 
HPV-18 Human papillomavirus type 18* Alphapapillomavirus genital mucosa 
HPV-27 Human papillomavirus type 27 Alphapapillomavirus skin 
HPV-38 Human papillomavirus type 38 Betapapillomavirus skin 
HPV-57 Human papillomavirus type 57 Alphapapillomavirus skin 
HPV-76 Human papillomavirus type 76 Betapapillomavirus skin 
HPV-93 Human papillomavirus type 93 Betapapillomavirus skin 
Domestic dogs   
CPV-1 Canis familiaris oral papillomavirus 
Formerly COVP 
Lambdapapillomavirus oral mucosa 
CPV-2 Canis familiaris papillomavirus type 2 Taupapillomavirus skin 
Domestic cattle 
  
BPV-1 Bos taurus papillomavirus type 1 Deltapapillomavirus skin 
BPV-2 Bos taurus papillomavirus type 2 Deltapapillomavirus skin 
BPV-3 Bos taurus papillomavirus type 3 Xipapillomavirus skin 
BPV-4 Bos taurus papillomavirus type 4 Xipapillomavirus oral/ oesophageal 
mucosa 
BPV-13 Bos taurus papillomavirus type 13 Deltapapillomavirus skin 
BPV-14 Bos taurus papillomavirus type 14 Deltapapillomavirus skin 
Horses    
EcPV-2 Equus caballus papillomavirus type 2 Dyoiotapapillomavirus genital mucosa 
Rabbits   
SfPV-1 Sylvilagus floridanus papillomavirus type 1 
Formerly cottontail rabbit papillomavirus 
Kappapapillomavirus skin 
OcPV-1 Oryctolagus cuniculus papillomavirus type 1 Kappapapillomavirus oral mucosa 
Mice    
MnPV-1 Mastomys natalensis papillomavirus type 1 Iotapapillomavirus skin 
MmuPV-1 Mus musculus papillomavirus type 1 Pipapillomavirus skin 
 
